As with other antihistaminic drugs, overdosage can produce the following symptoms: CNS depression accompanied by drowsiness (especially in adults), CNS stimulation and antimuscarinic effects (especially in children) including the following: excitation, ataxia, hallucinations, tonic or clonic spasms, mydriasis, dryness of the mouth, redness of the face, urine retention, fever and tachycardia. Blood hypotension is also possible. In its terminal phase, coma can be aggravated by cardiorespiratory colapse and death. There has been no report of a fatal outcome of Dimethindene overdosage.
Dimetindene (Fenistil) is an antihistamine/anticholinergic used orally and locally as an antipruritic.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aclidinium | The risk or severity of adverse effects can be increased when Dimetindene is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Dimetindene. |
| Mirabegron | The risk or severity of urinary retention can be increased when Dimetindene is combined with Mirabegron. |
| Potassium chloride | The risk or severity of gastrointestinal ulceration can be increased when Dimetindene is combined with Potassium chloride. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Dimetindene. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Dimetindene. |
| Tiotropium | The risk or severity of adverse effects can be increased when Dimetindene is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Dimetindene is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Dimetindene is combined with Umeclidinium. |
| Benzylpenicilloyl polylysine | Dimetindene may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Dimetindene. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dimetindene. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Dimetindene. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimetindene. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Dimetindene is combined with Glycopyrronium. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Dimetindene is combined with Botulinum toxin type A. |
| Glucagon | Dimetindene may increase the gastrointestinal motility reducing activities of Glucagon. |
| Sulpiride | Dimetindene may increase the anticholinergic activities of Sulpiride. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Dimetindene is combined with Botulinum toxin type B. |
| Eluxadoline | The risk or severity of constipation can be increased when Dimetindene is combined with Eluxadoline. |
| Ramosetron | The risk or severity of constipation can be increased when Dimetindene is combined with Ramosetron. |
| Amphetamine | Amphetamine may decrease the sedative activities of Dimetindene. |
| Phentermine | Phentermine may decrease the sedative activities of Dimetindene. |
| Pseudoephedrine | Pseudoephedrine may decrease the sedative activities of Dimetindene. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Dimetindene. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Dimetindene. |
| Lisdexamfetamine | Lisdexamfetamine may decrease the sedative activities of Dimetindene. |
| Mephentermine | Mephentermine may decrease the sedative activities of Dimetindene. |
| MMDA | MMDA may decrease the sedative activities of Dimetindene. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of Dimetindene. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Dimetindene. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dimetindene. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of Dimetindene. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Dimetindene. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of Dimetindene. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Dimetindene. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of Dimetindene. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of Dimetindene. |
| Ritobegron | Ritobegron may decrease the sedative activities of Dimetindene. |
| Mephedrone | Mephedrone may decrease the sedative activities of Dimetindene. |
| Methoxyphenamine | Methoxyphenamine may decrease the sedative activities of Dimetindene. |
| Gepefrine | Gepefrine may decrease the sedative activities of Dimetindene. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Dimetindene. |
| Phendimetrazine | Phendimetrazine may decrease the sedative activities of Dimetindene. |
| Naltrexone | The risk or severity of adverse effects can be increased when Dimetindene is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Dimetindene is combined with Bezitramide. |
| Tramadol | The risk or severity of adverse effects can be increased when Dimetindene is combined with Tramadol. |
| Morphine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Codeine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Dimetindene is combined with Hydromorphone. |
| Methadone | The risk or severity of adverse effects can be increased when Dimetindene is combined with Methadone. |
| Meperidine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Meperidine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Dimetindene is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Dimetindene is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Dimetindene is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Dimetindene is combined with Sufentanil. |
| Alfentanil | The risk or severity of adverse effects can be increased when Dimetindene is combined with Alfentanil. |
| Fentanyl | The risk or severity of adverse effects can be increased when Dimetindene is combined with Fentanyl. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Dimetindene is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Dimetindene is combined with Remifentanil. |
| Buprenorphine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Buprenorphine. |
| Hydrocodone | The risk or severity of adverse effects can be increased when Dimetindene is combined with Hydrocodone. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Dimetindene is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Dimetindene is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Dezocine. |
| Levacetylmethadol | The risk or severity of adverse effects can be increased when Dimetindene is combined with Levacetylmethadol. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Dimetindene is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Diamorphine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Dimetindene is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Dimetindene is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Dimetindene is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Dihydromorphine. |
| Tapentadol | The risk or severity of urinary retention and constipation can be increased when Dimetindene is combined with Tapentadol. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Dimetindene is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Dimetindene is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Dimetindene is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Dimetindene is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Dimetindene is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Dimetindene is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Nicomorphine. |
| Meptazinol | The risk or severity of adverse effects can be increased when Dimetindene is combined with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Dimetindene is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Dimetindene is combined with Carfentanil, C-11. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Dimetindene is combined with Benzhydrocodone. |
| Naloxegol | The risk or severity of adverse effects can be increased when Dimetindene is combined with Naloxegol. |
| Trospium | The risk or severity of adverse effects can be increased when Trospium is combined with Dimetindene. |
| Oxyphenonium | The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Dimetindene. |
| Benzatropine | The risk or severity of adverse effects can be increased when Benzatropine is combined with Dimetindene. |
| Disopyramide | The risk or severity of adverse effects can be increased when Disopyramide is combined with Dimetindene. |
| Metixene | The risk or severity of adverse effects can be increased when Metixene is combined with Dimetindene. |